Status:
UNKNOWN
Single-Center Prospective Study to Investigate the Difference in the Incidence of Contrast-Induced Nephropathy in High-Risk Patients With the Use of the Dye-Vert Plus System
Lead Sponsor:
CAMC Health System
Conditions:
AKI (Acute Kidney Injury) Due to Trauma
Eligibility:
All Genders
18-90 years
Phase:
PHASE4
Brief Summary
Coronary angiography (CAG) for diagnostic or therapeutic purposes such as percutaneous coronary intervention (PCI) is one of the common procedures which require the use of intravenous contrast media. ...
Detailed Description
Coronary angiography (CAG) for diagnostic or therapeutic purposes such as percutaneous coronary intervention (PCI) is one of the common procedures associated with Contrast-induced nephropathy (CIN). T...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- 18 years of age or older
- Scheduled to undergo CAG and/or PCI
- Baseline estimated glomerular filtration rate (eGFR) of ≥20 and ≤60 mL/ min/1.73 m2
- Serum creatinine \> 1.5mg/dl
- Obtaining a Cardiac catheterization.
- HTN/Diabetes
- Inpatient and outpatient
Exclusion
- Exclusion criteria:
- 91 years of age or older
- Serum creatinine \< 1.5mg/dl
- eGFR \> 60ml/min
- Pregnancy
- Dialysis
- Dye Allergy
Key Trial Info
Start Date :
February 3 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 3 2022
Estimated Enrollment :
1802 Patients enrolled
Trial Details
Trial ID
NCT04279457
Start Date
February 3 2020
End Date
February 3 2022
Last Update
February 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CAMC Health Education and Research Institute
Charleston, West Virginia, United States, 25304